Mobilization Strategies: HPC(A) Collections for Autologous Hematopoietic Cell Transplants

  • Nina WorelEmail author
Part of the Advances and Controversies in Hematopoietic Transplantation and Cell Therapy book series (ACHTCT)


Autologous hematopoietic cell transplantation with peripheral blood progenitor cells is a potentially curative treatment option for a variety of hematological diseases. Common strategies for peripheral blood CD34+ cell mobilization include the use of hematopoietic growth factors alone or in combination with chemotherapy, resulting in a marked increase of CD34+ cells in the peripheral blood. However, a significant proportion of patients fail to mobilize adequately. To enhance CD34+ cell release from the bone marrow, plerixafor, a chemokine receptor type 4 (CXCR4) antagonist, can be given in addition to growth factors ± chemotherapy.

In this chapter, we aim to show the best approaches to mobilize CD34+ cells and possibilities of optimizing collection yields in patients who mobilize poorly. We list risk factors for poor mobilization and, based on this factors, suggest appropriate mobilization regimens. As the most robust predictive factor for poor CD34+ cell collection is the CD34+ cell count in the peripheral blood before initiation of apheresis, a defined threshold helps to identify patients at risk and allows preemptive intervention to immediate rescue mobilization in these patients.

In addition, we discuss minimal and optimal CD34+ cell collected dose for sustained engraftment and engraftment characteristics associated with lower-than-optimal cell dose.


G-CSF Plerixafor Mobilization Collection Transplantation Progenitor cell CD34+ cell hematopoiesis 


  1. Abhyankar S, DeJarnette S, Aljitawi O, Ganguly S, Merkel D, McGuirk J (2012) A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 47(4):483–487PubMedCrossRefPubMedCentralGoogle Scholar
  2. Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ et al (1999) Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 39(6):555–560PubMedCrossRefPubMedCentralGoogle Scholar
  3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405CrossRefGoogle Scholar
  4. Bensinger W, DiPersio JF, McCarty JM (2009) Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 43(3):181–195PubMedCrossRefPubMedCentralGoogle Scholar
  5. Berger MG, Berger J, Richard C, Jeanpierre S, Nicolini FE, Tournilhac O et al (2008) Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization. Leukemia 22(11):2131–2134PubMedCrossRefGoogle Scholar
  6. Bolwell BJ, Pohlman B, Rybicki L, Sobecks R, Dean R, Curtis J et al (2007) Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 40(5):437–441PubMedCrossRefPubMedCentralGoogle Scholar
  7. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al (2008) AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 41(4):331–338PubMedCrossRefGoogle Scholar
  8. Chabannon C, Bijou F, Miclea JM, Milpied N, Grouin JM, Mohty M (2015) A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the “on-demand” scheme of administration at French autologous hematopoietic stem cell transplant programs. Transfusion 55(9):2149–2157PubMedCrossRefGoogle Scholar
  9. Chen AI, Bains T, Murray S, Knight R, Shoop K, Bubalo J et al (2012) Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. Bone Marrow Transplant 47(12):1526–1529PubMedCrossRefGoogle Scholar
  10. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK (2011) Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 46(1):64–69PubMedCrossRefPubMedCentralGoogle Scholar
  11. D’Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S et al (2011) The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 46(3):356–363PubMedCrossRefPubMedCentralGoogle Scholar
  12. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al (2009a) Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 27(28):4767–4773CrossRefGoogle Scholar
  13. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al (2009b) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113(23):5720–5726PubMedCrossRefPubMedCentralGoogle Scholar
  14. Fadini GP, Avogaro A (2013) Diabetes impairs mobilization of stem cells for the treatment of cardiovascular disease: a meta-regression analysis. Int J Cardiol 168(2):892–897PubMedCrossRefPubMedCentralGoogle Scholar
  15. Genzyme Ltd: Suffolk U. Mozobil [Product information] (2009). Accessed 28 Aug 2013
  16. Gertz MA (2010) Current status of stem cell mobilization. Br J Haematol 150(6):647–662PubMedCrossRefPubMedCentralGoogle Scholar
  17. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al (2009) Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 43(8):619–625PubMedCrossRefPubMedCentralGoogle Scholar
  18. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A et al (1989) Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 2(8663):580–585PubMedCrossRefPubMedCentralGoogle Scholar
  19. Giralt S, Costa L, Schriber J, DiPersio J, Maziarz R, McCarty J et al (2014) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Tr 20(3):295–308. EnglishCrossRefGoogle Scholar
  20. Hill BT, Rybicki L, Smith S, Dean R, Kalaycio M, Pohlman B et al (2011) Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. Leuk Lymphoma 52(6):986–993PubMedCrossRefGoogle Scholar
  21. Jillella AP, Ustun C (2004) What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? Stem Cells Dev 13(6):598–606PubMedCrossRefGoogle Scholar
  22. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al (2007) Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21(9):2035–2042PubMedCrossRefGoogle Scholar
  23. Mohty M, Ho AD (2011) In and out of the niche: perspectives in mobilization of hematopoietic stem cells. Exp Hematol 39(7):723–729PubMedCrossRefGoogle Scholar
  24. Mohty M, Hubel K, Kroger N, Aljurf M, Apperley J, Basak GW et al (2014) Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 49(7):865–872. EnglishPubMedCrossRefGoogle Scholar
  25. Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F et al (2012) Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplant 47(3):342–351PubMedCrossRefGoogle Scholar
  26. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P et al (2016) Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually. Bone Marrow Transplant 51(6):786–792. EnglishPubMedPubMedCentralCrossRefGoogle Scholar
  27. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P et al (2002) Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin’s lymphoma. Bone Marrow Transplant 29(4):285–290PubMedCrossRefGoogle Scholar
  28. Perez-Simon JA, Caballero MD, Corral M, Nieto MJ, Orfao A, Vazquez L et al (1998) Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 38(4):385–391PubMedCrossRefGoogle Scholar
  29. Perez-Simon JA, Martin A, Caballero D, Corral M, Nieto MJ, Gonzalez M et al (1999) Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 24(12):1279–1283PubMedCrossRefGoogle Scholar
  30. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L et al (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3(7):687–694CrossRefGoogle Scholar
  31. Platzbecker U, Prange-Krex G, Bornhauser M, Koch R, Soucek S, Aikele P et al (2001) Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 41(2):184–189PubMedCrossRefPubMedCentralGoogle Scholar
  32. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA et al (2008) Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 14(7):807–816PubMedPubMedCentralCrossRefGoogle Scholar
  33. Pusic I, DiPersio JF (2008) The use of growth factors in hematopoietic stem cell transplantation. Curr Pharm Des 14(20):1950–1961PubMedCrossRefPubMedCentralGoogle Scholar
  34. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF et al (2008) Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 14(9):1045–1056PubMedCrossRefPubMedCentralGoogle Scholar
  35. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C (2000) Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol 18(6):1360–1377CrossRefGoogle Scholar
  36. Stiff PJ (1999) Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 23(Suppl 2):S29–S33PubMedCrossRefPubMedCentralGoogle Scholar
  37. Stroncek D, Shawker T, Follmann D, Leitman SF (2003) G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 43(5):609–613PubMedCrossRefPubMedCentralGoogle Scholar
  38. Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL (2007) Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 40(3):185–192PubMedCrossRefPubMedCentralGoogle Scholar
  39. Vellenga E, van Agthoven M, Croockewit AJ, Verdonck LF, Wijermans PJ, van Oers MH et al (2001) Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol 114(2):319–326PubMedCrossRefPubMedCentralGoogle Scholar
  40. Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D et al (2002) Autologous transplantation for aggressive non-Hodgkin’s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol Off J Am Soc Clin Oncol 20(9):2344–2352CrossRefGoogle Scholar
  41. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86(10):3961–3969PubMedCrossRefGoogle Scholar
  42. Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G et al (2011) Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 51(5):968–975PubMedCrossRefGoogle Scholar
  43. Worel N, Fritsch G, Agis H, Bohm A, Engelich G, Leitner GC et al (2017) Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. J Clin Apher 32:224–234PubMedCrossRefGoogle Scholar
  44. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K et al (2010) Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 16(4):490–499PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Blood Group Serology and Transfusion MedicineMedical University of ViennaViennaAustria

Personalised recommendations